VK 0214
Alternative Names: MB-10866; VK 0214Latest Information Update: 27 Mar 2025
At a glance
- Originator Metabasis Therapeutics
- Developer Viking Therapeutics
- Class Acetates; Benzene derivatives; Phosphorus compounds; Small molecules
- Mechanism of Action Thyroid hormone receptor beta agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Adrenoleucodystrophy
Most Recent Events
- 27 Mar 2025 VK 0214 is available for licensing as of 31 Dec 2024
- 08 Nov 2024 Viking Therapeutics completes the phase I trial in Adrenoleucodystrophy in USA, France, Germany, Italy and United Kingdom (PO) after April 2022 (NCT04973657)
- 09 Oct 2024 Efficacy and adverse events data from a phase-I clinical trials in Adrenoleucodystrophy released by Viking Therapeutics